Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for…
NEW HAVEN, Conn., July 30, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence…
The esteemed annual symposium explores the most urgent questions facing our future BOSTON, July 29, 2024 /PRNewswire/ -- The Chopra…
AAIC Poster Presentation Highlights XPro's™ Significant Effects on a Wide Range of Synaptic Proteins and Pathways BOCA RATON, Fla., July…
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,…
This data supports the potential of plasma ASC levels as a biomarker for early stages of cognitive decline, based on…
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage…
Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose…
$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the…
If approved, Yuvanci® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson’s comprehensive…
